Voriconazole Powder, For Suspension
NDC Package 72673-111-30

11-digit billing NDC: 72673011130

Package Information

Voriconazole powders is voriconazole for Oral Suspension is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. This formulation utilizes a powder, for suspension delivery system. Marketed by Zhejiang Poly Pharm Co., Ltd., this product is identified by NDC 72673-111 and is authorized under FDA application ANDA216805.

Identification & Billing

NDC Package Code
72673-111-30
Package Description
1 BOTTLE in 1 CARTON / 75 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
72673011130
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Voriconazole
Non-Proprietary Name
Voriconazole
Substance Name
Voriconazole
Dosage Form
Powder, For Suspension - An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle).
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Voriconazole for Oral Suspension is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents. Caution should be used when prescribing voriconazole to patients with hypersensitivity to other azoles.Coadministration of pimozide, quinidine or ivabradine with voriconazole is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes [see Drug Interactions ( 7)] . Coadministration of voriconazole with sirolimus is contraindicated because voriconazole significantly increases sirolimus concentrations [see Drug Interactions ( 7) and Clinical Pharmacology ( 12.3)] . Coadministration of voriconazole with rifampin, carbamazepine, long-acting barbiturates, or St John’s Wort is contraindicated because these drugs are likely to decrease plasma voriconazole concentrations significantly [see Drug Interactions ( 7) and Clinical Pharmacology ( 12.3)] . Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg every 24 hours or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations [see Drug Interactions ( 7) and Clinical Pharmacology ( 12.3)] . Coadministration of voriconazole with high-dose ritonavir (400 mg every 12 hours) is contraindicated because ritonavir (400 mg every 12 hours) significantly decreases plasma voriconazole concentrations. Coadministration of voriconazole and low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole [see Drug Interactions ( 7) and Clinical Pharmacology ( 12.3)] . Coadministration of voriconazole with rifabutin is contraindicated since voriconazole significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations [see Drug Interactions ( 7) and Clinical Pharmacology ( 12.3)] . Coadministration of voriconazole with ergot alkaloids (ergotamine and dihydroergotamine) is contraindicated because voriconazole may increase the plasma concentration of ergot alkaloids, which may lead to ergotism [see Drug Interactions ( 7)] . Coadministration of voriconazole with naloxegol is contraindicated because voriconazole may increase plasma concentrations of naloxegol which may precipitate opioid withdrawal symptoms [see Drug Interactions ( 7)] . Coadministration of voriconazole with tolvaptan is contraindicated because voriconazole may increase tolvaptan plasma concentrations and increase risk of adverse reactions [see Drug Interactions ( 7)] . Coadministration of voriconazole with venetoclax at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions ( 7)] . Coadministration of voriconazole with lurasidone is contraindicated since it may result in significant increases in lurasidone exposure and the potential for serious adverse reactions [see Drug Interactions ( 7)] . Coadministration of voriconazole with finerenone is contraindicated since it may result in significant increases in finerenone exposure and the potential for serious adverse reactions [see Drug Interactions ( 7)]

Regulatory & Marketing

Labeler Name
Zhejiang Poly Pharm Co., Ltd.
Product Type
Human Prescription Drug
FDA Application #
ANDA216805
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-11-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72673-111-30 identifies a specific commercial package of 1 bottle in 1 carton / 75 ml in 1 bottle of Voriconazole, a human prescription drug labeled by Zhejiang Poly Pharm Co., Ltd.. This powder, for suspension is formulated for oral use and contains voriconazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zhejiang Poly Pharm Co., Ltd. on April 11, 2025. The current certification is valid through December 31, 2026.

How is this Zhejiang Poly Pharm Co., Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72673011130. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72673-111-30
11-Digit CMS (5-4-2)
72673-0111-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.